Global Milbemycinoxime API Market Growth 2026-2032
Description
The global Milbemycinoxime API market size is predicted to grow from US$ 33.45 million in 2025 to US$ 52.66 million in 2032; it is expected to grow at a CAGR of 6.6% from 2026 to 2032.
Milbemime is a novel semi-synthetic macrolide anthelmintic, an oxime derivative of milbemime A3 and A4. The molecular weight of A3 oxime is 541.7, and that of A4 oxime is 555.7. In application, milbemime can be used alone or in combination with drugs such as nitenpyram, flufenoxuron, spinosad, and praziquantel to form compound preparations. These preparations are effective in controlling internal parasites such as canine heartworm, hookworm, roundworm, and whipworm, as well as external parasites such as folliculitis, lice, and fleas. Milbemime is an agonist of the γ-aminobutyric acid (GABA) neurotransmitter in nerve cells and can also bind to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates. In both cases, it blocks the nerve signals of the parasites, ultimately leading to paralysis, loss of muscle contraction, cessation of feeding, and death of the parasite. In 2025, global sales of milbemycinoxime API reached approximately 2.5 tons, with an average price of about US$14,000 per kilogram. The industry's average gross profit margin exceeded 55%.
Against the backdrop of continuous upgrading of the global veterinary drug industry and rapid development of the pet economy, the stable supply and technological capabilities of core active pharmaceutical ingredients (APIs) are becoming crucial factors determining industry competitiveness. As a key active ingredient widely used in parasite control, Milbemycin API is gradually evolving from a single-function ingredient into a fundamental substance supporting the modern veterinary drug system, with its market value and strategic importance continuously increasing.
Milbemycin is a macrolide compound primarily used to kill internal and external parasites, and is widely used in deworming preparations for companion animals such as dogs and cats. Its mechanism of action is well-defined, its spectrum of action is broad, and its safety profile is high, making it one of the core components in current pet deworming drug systems. As the source of efficacy in formulations, the quality stability, purity control, and batch consistency of Milbemycin API directly affect the safety and market acceptance of downstream veterinary drug products, highlighting its fundamental role in the entire industry chain.
From a market structure perspective, global demand for Milbemycin-related formulations is highly correlated with the growth in the pet population and the increasing standardization of pet healthcare. With the increasing adoption of companion animals in households, growing awareness of medical care, and the growing popularity of regular deworming, the penetration rate of milbemime-based deworming products continues to rise in both mature and emerging markets. This trend provides stable and long-term demand support for the milbemime API market, making it one of the most promising segments in the veterinary drug API sector.
From the supply side, the production of milbemime API has certain technical and process barriers. Its synthetic route is complex, and process control requirements are high, placing high demands on the stability of fermentation or chemical synthesis processes, impurity control capabilities, and quality systems. This gives API companies with mature process accumulation and sound quality management systems a greater competitive advantage in the market. As global veterinary drug regulations become stricter, milbemime API suppliers that meet international standards and have continuous supply capabilities will find it easier to enter the supply chains of mainstream veterinary drug companies.
In terms of supply chain collaboration, milbemime API is gradually forming closer cooperative relationships with downstream formulation companies. Pharmaceutical formulation companies are increasingly demanding higher standards for the stability, compliance, and traceability of raw material sources. This has transformed active pharmaceutical ingredients (APIs) from price-driven products into crucial foundations for cooperation driven by quality and supply capacity. This shift is propelling the milbemime API market from fragmented competition to a quality-oriented approach and long-term partnerships.
Regional markets show stable demand for milbemime formulations in mature markets like Europe, the US, and Japan, with high requirements for API quality and compliance. Meanwhile, emerging markets in Asia and Latin America are experiencing more significant demand growth, driven by increasing pet numbers and the standardization of the veterinary drug market. As a major global production base for veterinary drug APIs, China is gradually enhancing its technological capabilities and international market participation in the milbemime API sector, possessing the potential to extend into higher segments of the global supply chain.
Looking ahead, the milbemime API market will focus more on high-quality, compliant, and large-scale supply capabilities. With the continuous improvement of veterinary drug regulations, competition among API companies regarding process stability, quality consistency, and international registration support capabilities will intensify further. Meanwhile, the development of companion animal medicine towards long-term and preventative medication will also bring continuous and stable demand growth for milbemoxime raw materials.
LP Information, Inc. (LPI) ' newest research report, the “Milbemycinoxime API Industry Forecast” looks at past sales and reviews total world Milbemycinoxime API sales in 2025, providing a comprehensive analysis by region and market sector of projected Milbemycinoxime API sales for 2026 through 2032. With Milbemycinoxime API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Milbemycinoxime API industry.
This Insight Report provides a comprehensive analysis of the global Milbemycinoxime API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Milbemycinoxime API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Milbemycinoxime API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Milbemycinoxime API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Milbemycinoxime API.
This report presents a comprehensive overview, market shares, and growth opportunities of Milbemycinoxime API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
98% Purity
Purity Greater than 98%
Segmentation by Application:
Dog
Cat
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
JIANGSU LINGYUN PHARMACEUTICAL CO.LTD
Joincare Pharmaceutical Group Industry Co., Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Milbemycinoxime API market?
What factors are driving Milbemycinoxime API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Milbemycinoxime API market opportunities vary by end market size?
How does Milbemycinoxime API break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Milbemime is a novel semi-synthetic macrolide anthelmintic, an oxime derivative of milbemime A3 and A4. The molecular weight of A3 oxime is 541.7, and that of A4 oxime is 555.7. In application, milbemime can be used alone or in combination with drugs such as nitenpyram, flufenoxuron, spinosad, and praziquantel to form compound preparations. These preparations are effective in controlling internal parasites such as canine heartworm, hookworm, roundworm, and whipworm, as well as external parasites such as folliculitis, lice, and fleas. Milbemime is an agonist of the γ-aminobutyric acid (GABA) neurotransmitter in nerve cells and can also bind to glutamate-gated chloride ion channels in the nerve and muscle cells of invertebrates. In both cases, it blocks the nerve signals of the parasites, ultimately leading to paralysis, loss of muscle contraction, cessation of feeding, and death of the parasite. In 2025, global sales of milbemycinoxime API reached approximately 2.5 tons, with an average price of about US$14,000 per kilogram. The industry's average gross profit margin exceeded 55%.
Against the backdrop of continuous upgrading of the global veterinary drug industry and rapid development of the pet economy, the stable supply and technological capabilities of core active pharmaceutical ingredients (APIs) are becoming crucial factors determining industry competitiveness. As a key active ingredient widely used in parasite control, Milbemycin API is gradually evolving from a single-function ingredient into a fundamental substance supporting the modern veterinary drug system, with its market value and strategic importance continuously increasing.
Milbemycin is a macrolide compound primarily used to kill internal and external parasites, and is widely used in deworming preparations for companion animals such as dogs and cats. Its mechanism of action is well-defined, its spectrum of action is broad, and its safety profile is high, making it one of the core components in current pet deworming drug systems. As the source of efficacy in formulations, the quality stability, purity control, and batch consistency of Milbemycin API directly affect the safety and market acceptance of downstream veterinary drug products, highlighting its fundamental role in the entire industry chain.
From a market structure perspective, global demand for Milbemycin-related formulations is highly correlated with the growth in the pet population and the increasing standardization of pet healthcare. With the increasing adoption of companion animals in households, growing awareness of medical care, and the growing popularity of regular deworming, the penetration rate of milbemime-based deworming products continues to rise in both mature and emerging markets. This trend provides stable and long-term demand support for the milbemime API market, making it one of the most promising segments in the veterinary drug API sector.
From the supply side, the production of milbemime API has certain technical and process barriers. Its synthetic route is complex, and process control requirements are high, placing high demands on the stability of fermentation or chemical synthesis processes, impurity control capabilities, and quality systems. This gives API companies with mature process accumulation and sound quality management systems a greater competitive advantage in the market. As global veterinary drug regulations become stricter, milbemime API suppliers that meet international standards and have continuous supply capabilities will find it easier to enter the supply chains of mainstream veterinary drug companies.
In terms of supply chain collaboration, milbemime API is gradually forming closer cooperative relationships with downstream formulation companies. Pharmaceutical formulation companies are increasingly demanding higher standards for the stability, compliance, and traceability of raw material sources. This has transformed active pharmaceutical ingredients (APIs) from price-driven products into crucial foundations for cooperation driven by quality and supply capacity. This shift is propelling the milbemime API market from fragmented competition to a quality-oriented approach and long-term partnerships.
Regional markets show stable demand for milbemime formulations in mature markets like Europe, the US, and Japan, with high requirements for API quality and compliance. Meanwhile, emerging markets in Asia and Latin America are experiencing more significant demand growth, driven by increasing pet numbers and the standardization of the veterinary drug market. As a major global production base for veterinary drug APIs, China is gradually enhancing its technological capabilities and international market participation in the milbemime API sector, possessing the potential to extend into higher segments of the global supply chain.
Looking ahead, the milbemime API market will focus more on high-quality, compliant, and large-scale supply capabilities. With the continuous improvement of veterinary drug regulations, competition among API companies regarding process stability, quality consistency, and international registration support capabilities will intensify further. Meanwhile, the development of companion animal medicine towards long-term and preventative medication will also bring continuous and stable demand growth for milbemoxime raw materials.
LP Information, Inc. (LPI) ' newest research report, the “Milbemycinoxime API Industry Forecast” looks at past sales and reviews total world Milbemycinoxime API sales in 2025, providing a comprehensive analysis by region and market sector of projected Milbemycinoxime API sales for 2026 through 2032. With Milbemycinoxime API sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Milbemycinoxime API industry.
This Insight Report provides a comprehensive analysis of the global Milbemycinoxime API landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Milbemycinoxime API portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Milbemycinoxime API market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Milbemycinoxime API and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Milbemycinoxime API.
This report presents a comprehensive overview, market shares, and growth opportunities of Milbemycinoxime API market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
98% Purity
Purity Greater than 98%
Segmentation by Application:
Dog
Cat
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
JIANGSU LINGYUN PHARMACEUTICAL CO.LTD
Joincare Pharmaceutical Group Industry Co., Ltd
Zhejiang Hisun Pharmaceutical Co., Ltd
Hubei Honch Pharmaceutical Co.,Ltd
Key Questions Addressed in this Report
What is the 10-year outlook for the global Milbemycinoxime API market?
What factors are driving Milbemycinoxime API market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Milbemycinoxime API market opportunities vary by end market size?
How does Milbemycinoxime API break out by Type, by Application?
Please note: The report will take approximately 2 business days to prepare and deliver.
Table of Contents
83 Pages
- *This is a tentative TOC and the final deliverable is subject to change.*
- 1 Scope of the Report
- 2 Executive Summary
- 3 Global by Company
- 4 World Historic Review for Milbemycinoxime API by Geographic Region
- 5 Americas
- 6 APAC
- 7 Europe
- 8 Middle East & Africa
- 9 Market Drivers, Challenges and Trends
- 10 Manufacturing Cost Structure Analysis
- 11 Marketing, Distributors and Customer
- 12 World Forecast Review for Milbemycinoxime API by Geographic Region
- 13 Key Players Analysis
- 14 Research Findings and Conclusion
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
